Background: Latest topic for Type 2 diabetes (T2D) would be oral semaglutide (Rybelsus).
Case presentation: Patient is 74-year-old female with T2D. She showed 65.5 kg (BMI 28.7 kg/m2) and HbA1c 7.4% in Feb 2022.
Results: She started Rybelsus 3-7mg/day, and then she had clinical effects as 58kg and 6.0% in June 2022, respectively.
Discussion: Rybelsus is characteristic for its clinical efficacy of improvement for glucose variability and body weight. Various data were from Semaglutide Treatment Effect in People with Obesity (STEP) and Peptide Innovation for Early diabetes treatment (PIONEER) studies. This report becomes hopefully useful reference for diabetic research